Biosig technologies appoints mr. ferdinand groenewald to position of interim chief financial officer and principal accounting officer

Westport, ct, june 10, 2024 (globe newswire) -- biosig technologies, inc. (nasdaq: bsgm) or (“biosig” or "company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of mr. ferdinand groenewald to the position of interim chief financial officer.   personal bio, ferdinand groenewald, age 39ferdinand groenewald is a certified public accountant with significant experience in finance and accounting. he currently serves as vice president, finance at alaunos therapeutics, inc. previously, mr. groenewald served as an independent outside director at syla technologies co., ltd.; an independent director at heartcore enterprises, inc.; an independent director at sushi ginza onodera, inc.; an accountant at wrinkle, gardner & co. pc; a senior staff accountant at financial consulting strategies llc; a controller, vp-finance & accounting officer at sadot group, inc. and a chief financial officer at the same company; and chief accounting officer & vp-finance at muscle maker development llc. mr. groenewald obtained an undergraduate degree from the university of south africa.
BSGM Ratings Summary
BSGM Quant Ranking